## Abstract Enzyme‐replacement treatment for metabolic storage disorders has been widely studied using model cell culture systems. This study determines the long‐term fate of human hexosaminidase A supplied to Tay‐Sachs disease brain and lung cells. Hex A retention studies showed that the incorpora
Tay-sachs disease brain cells in culture: Mobilization of stored GM2 after concanavalin A-mediated uptake of hexosaminidase A
✍ Scribed by Dr. Linda M. Hoffman; Steven E. Brooks; Daniel Amsterdam; John Oropello; Larry Schneck
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 324 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0360-4012
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A human Tay‐Sachs disease (TSD) fetal‐brain‐cell line is a useful model for the disease since the cells lack hexosaminidase A and accumulate the ganglioside, G~M2~. This brain‐cell line was used to assess the effect of hexosaminidase A treatment on G~M2~ storage material. Entry of placental hexosaminidase A into the cells was obtained by pretreatment of the cultures with concanavalin A. Cells were analyzed periodically during six days. During the course of the experiment, G~M2~ in the cells decreased by approximately 50%. A substantial amount of hexosaminidase A was maintained in the cultures throughout the experiment. This strategy was successful in mobilizing stored G~M2~ in TSD brain‐cell cultures. Therefore, the activating factor needed for hexosaminidase A activity must be present in TSD‐cultured brain cells.
📜 SIMILAR VOLUMES